DNB Asset Management AS Raises Stake in Elevance Health, Inc. $ELV

Posted by Brenda Bartman on May 17th, 2026

DNB Asset Management AS raised its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 75.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 74,306 shares of the company’s stock after buying an additional 32,048 shares during the period. DNB Asset Management AS’s holdings in Elevance Health were worth $26,048,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. grew its holdings in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the period. Activest Wealth Management boosted its holdings in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the period. Rossby Financial LCC boosted its holdings in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares during the period. ORG Partners LLC boosted its holdings in Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in Elevance Health during the 4th quarter valued at about $38,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health Price Performance

Shares of NYSE ELV opened at $392.74 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $412.96. The firm has a market capitalization of $85.29 billion, a PE ratio of 16.71, a price-to-earnings-growth ratio of 2.23 and a beta of 0.66. The stock’s 50-day simple moving average is $322.88 and its 200-day simple moving average is $334.02.

Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities research analysts forecast that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ELV shares. Robert W. Baird raised their target price on Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Sanford C. Bernstein raised their target price on Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a report on Friday, April 24th. The Goldman Sachs Group raised their target price on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a report on Friday, April 24th. JPMorgan Chase & Co. raised their target price on Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Finally, Wells Fargo & Company lowered their target price on Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Thirteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $384.58.

View Our Latest Research Report on ELV

About Elevance Health

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.